Olfactive is building an alternative path: activate the bodys own signaling through receptor-targeted food ligandsdesigned for long-term use and broad distribution
To view or add a comment, sign in Samjin Pharmaceutical applies for domestic Phase 1 clinical trials of novel inflammation and immunology drug candidate SJN314 Samjin Pharmaceutical (hereinafter referred to as Samjin Pharm) announced on February 4 that it has submitted an Investigational New Drug (IND) application to the Ministry of Food and Drug Safety (MFDS) for a Phase 1 clinical trial of SJN314 (development code). The candidate represents a key asset within the company's novel drug research pipeline focused on Inflammation & Immunology. SJN314 is an orally administered, small-molecule inhibitor of Mas-related G-protein-coupled receptor X2 (MRGPRX2), being developed for the treatment of inflammatory conditions such as chronic spontaneous urticaria (CSUR) and atopic dermatitis
Methylcobalamin, the methylated form of vitamin B12, is particularly vulnerable: studies published in the International Journal of Pharmaceutics demonstrate that it undergoes photolytic and thermal degradation at temperatures above 25C, with degradation rates accelerating exponentially above 30C
Weight loss drugs are making people hear their own blood, eyes moving, Darth Vader voice See more of our coverage in your search results
With 2 amazing flavours (Citrus Freeze and Watermelon Frost), you can enjoy great taste without the insulin spike
doi: 10.1111/dom.13024 28 BastinMAndreelliF
